We are monitoring the impact of COVID-19 on North America Liquid Biopsy Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 890
Share on
Share on

North America Liquid Biopsy Market Research Report – Segmented By Cancer Type, Sample Type, Diagnostic Approach, End Users, Country (the United States, Canada and Rest of North America) - Industry Analysis, Size, Share, Growth, Trends, And Forecasts (2021 to 2026)

Pulished: April, 2021
ID: 890
Pages: 145

North America Liquid Biopsy Market Size (2021 to 2026)

The North American Liquid Biopsy Market size is expected to grow at a CAGR of 19.6% during the forecast period. The market size is estimated to value USD 717 million by 2026 from USD 293 million in 2021.

Liquid biopsies offer an easy and effective way of sample collection, invasive treatment, and faster diagnosis leading to rising demand for these devices and, further, expected to boost the liquid biopsy market in North America during the forecast period. Owing to a wide range of applications of liquid biopsies,

The key drivers fueling the growth of the North American market are the rise in the occurrence of cancer, particularly colorectal cancer, leading to an increase in demand for non-invasive techniques like liquid biopsy tests. In addition, patient comfort, growing demand for specific and reliable assay, real-time treatment monitoring, early detection of tumors, improvements in health infrastructure, expensive techniques, and obtained drug resistance are further driving the market growth.

The significant restraints opposing the growth of the North American market are Lack of reimbursements and continuously changing regulations of laboratory-developed tests leading to increasing costs of new tests and delays in their release in the market, low rate of specificity and sensitivity,

Key players in the market show interest in increasing investments and expanding product portfolios through research and developments. By adopting innovative strategies, these are likely to offer lucrative opportunities for the growth of the North American market during the forecast period.  

This research report on the North American Liquid Biopsy Market has been segmented and sub-segmented market into the following categories:

By Cancer Type: 

  • Lung Cancer
  • Pancreatic Cancer
  • Leukemia
  • Other Visceral Cancers

By Diagnostic Approach: 

  • Circulating Tumour cells (CTC)
  • Circulating Tumour DNA (ctDNA)
  • RNA in exosomes
  • Extra-Cellular Vesicles

By End-Users: 

  • Reference Laboratories
  • Hospital/Physician Laboratories
  • Academic and Research Centers
  • Other End Users

By Country: 

  • The United States
  • Canada
  • Rest of North America

Regionally, North America is leading the global market. This market is on high growth in North America as colorectal cancer stands fourth most commonly diagnosed cancer. In addition, there is a lot of research going on for the detection of colorectal cancer.

The Liquid Biopsy market in the United States is expected to grow at a robust CAGR during the forecast period. The U.S. is researching liquid biopsy actively and treating patients at a very early stage of cancer. In the U.S., the adoption of liquid biopsy to leave outpatients from targeted therapy has seen much slower clinical acceptance. A liquid biopsy is an attractive tool for cancer screening at the initial stage, which is anticipated to propel the market's demand. The U.S. is facing a few challenges because of the less funding given by the government. The emergence of advancement in technology in research centers is significantly influencing the demand of the market. Awareness of this technique will drive the regional Liquid Biopsy market. 

The Canadian liquid biopsy market is growing steadily in Canada. This is because raising cancer incidence is one of the leading factors responsible for diagnosing many patients in this region. In Canada, mainly Newfoundland, Labrador, Ontario, Nova Scotia shows the highest cancer incidence rate. A liquid biopsy technique is correctly used to detect the early detect tumor from a small number of blood samples involved in metastasis.

The highest mortality rate is due to the increasing death rate by cancer. Liquid biopsy facilitates the surgeon to understand the cancer stage, which is driving the growth of the cancer cells. It also may help to seek better treatment at the earliest stage to treat cancer effectively. These factors are prompting demand for the liquid biopsy market in Canada. While advancing technology rapidly, getting approval from regulatory authority are significant challenges in front of companies. The increasing alcohol consumption and smoking rate day by day and many researchers working on detecting colorectal cancer are enhancing the market's growth.


Some of the promising companies operating in the North American liquid biopsy market are Janssen Diagnostics, Qiagen, Rarecells SAS, Silicon Biosystems, SRI International, Myriad Genetics, Natera, Personal Genome Diagnostics, Sysmex Inostics, Trovagene, Exosome Diagnostics, Exosome Sciences, and HansaBiomed OU.

1. Introduction                                                 

                1.1 Market Definition                                    

                1.2 Study Deliverables                                  

                1.3 Base Currency, Base Year and Forecast Periods                                           

                1.4 General Study Assumptions                                

2. Research Methodology                                                           

                2.1 Introduction                                              

                2.2 Research Phases                                      

                                2.2.1 Secondary Research                            

                                2.2.2 Primary Research                 

                                2.2.3 Econometric Modelling                     

                                2.2.4 Expert Validation                  

                2.3 Analysis Design                                         

                2.4 Study Timeline                                          

3. Overview                                                      

                3.1 Executive Summary                                

                3.2 Key Inferences                                         

                3.3 New Developments                                

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                                      

                4.1 Market Drivers                                          

                4.2 Market Restraints                                    

                4.3 Key Challenges                                         

                4.4 Current Opportunities in the Market                               

5. Market Segmentation                                                              

                5.1 By Cancer Type                                         

                                5.1.1 Lung Cancer                           

                                5.1.2 Pancreatic Cancer                

                                5.1.3 Leukemia                

                                5.1.4 Other Visceral Cancers                       

                5.2 By Sample Type                                        

                                5.2.1 Blood                        

                                5.2.2 Urine                         

                                5.2.3 Plasma                      

                                5.2.4 Saliva                         

                                5.2.5 Cerebrospinal                        

                5.3 By Diagnostic Approach                                        

                                5.3.1 Circulating Tumour cells (CTC)                        

                                5.3.2 Circulating Tumour DNA (ctDNA)                  

                                5.3.3 RNA in exosomes                 

                                5.3.4 Extra-Cellular Vesicles                        

                5.4 By End Users                                             

                                5.4.1 Reference Laboratories                     

                                5.4.2 Hospital/Physician Laboratories                     

                                5.4.3 Academic and Research Centers                    

                                5.4.4 Other End Users                   

6. Geographical Analysis                                                              

                                6.1 Introduction                              

                                6.2 United States                            

                                6.3 Canada                         

7. Strategic Analysis                                                       

                7.1 PESTLE analysis                                         

                                7.1.1 Political                     

                                7.1.2 Economic                 

                                7.1.3 Social                         

                                7.1.4 Technological                         

                                7.1.5 Legal                          

                                7.1.6 Environmental                      

                7.2 Porter’s Five analysis                                              

                                7.2.1 Bargaining Power of Suppliers                        

                                7.2.2 Bargaining Power of Consumers                    

                                7.2.3 Threat of New Entrants                     

                                7.2.4 Threat of Substitute Products and Services               

                                7.2.5 Competitive Rivalry within the Industry                      

8. Market Leaders' Analysis                                                        

                8.1 Janssen Diagnostics                                

                                8.1.1 Overview                

                                8.1.2 Product Analysis                   

                                8.1.3 Strategic Evaluation and Operations                            

                                8.1.4 Financial analysis                  

                                8.1.5 Legal issues                            

                                8.1.6 Recent Developments                       

                                8.1.7 SWOT analysis                       

                                8.1.8 Analyst View                          

                8.2 Qiagen                                         

                8.3 Rarecells SAS                                             

                8.4 Silicon Biosystems                                   

                8.5 SRI International                                      

                8.6 Myriad Genetics                                      

                8.7 Natera                                          

                8.8 Personal Genome Diagnostics                                            

                8.9 Sysmex Inostics                                        

                8.10 Trovagene                                

                8.11 Exosome Diagnostics                                           

                8.12 HansaBiomed OU                                  

9. Competitive Landscape                                                           

                9.1 Market share analysis                                            

                9.2 Merger and Acquisition Analysis                                        

                9.3 Agreements, collaborations and Joint Ventures                                          

                9.4 New Product Launches                                          

10. Expert Opinions                                                        

                10.1 Market Outlook                                     

                10.2 Investment Opportunities                                 


                a) List of Tables                                

                b) List of Figures                                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. North America Liquid Biopsy Market, By Region, From 2021 to 2026 (USD Billion)
  2. North America Liquid Biopsy Market, By Cancer Type, From 2021 to 2026 (USD Billion)
  3. North America Lung Cancer Market, By Region, From 2021 to 2026 (USD Billion)
  4. North America Pancreatic Cancer Market, By Region, From 2021 to 2026 (USD Billion)
  5. North America Leukemia Market, By Region, From 2021 to 2026 (USD Billion)
  6. North America Other Visceral Cancers Market, By Region, From 2021 to 2026 (USD Billion)
  7. North America Liquid Biopsy Market, By Sample Type, From 2021 to 2026 (USD Billion)
  8. North America Blood Market, By Region, From 2021 to 2026 (USD Billion)
  9. North America Urine Market, By Region, From 2021 to 2026 (USD Billion)
  10. North America Plasma Market, By Region, From 2021 to 2026 (USD Billion)
  11. North America Saliva Market, By Region, From 2021 to 2026 (USD Billion)
  12. North America Cerebrospinal Market, By Region, From 2021 to 2026 (USD Billion)
  13. North America Liquid Biopsy Market, By Diagnostic Approach, From 2021 to 2026 (USD Billion)
  14. North America Circulating Tumour cells (CTC) Market, By Region, From 2021 to 2026 (USD Billion)
  15. North America Circulating Tumour DNA (ctDNA) Market, By Region, From 2021 to 2026 (USD Billion)
  16. North America RNA in exosomes Market, By Region, From 2021 to 2026 (USD Billion)
  17. North America Extra-Cellular Vesicles Market, By Region, From 2021 to 2026 (USD Billion)
  18. North America Liquid Biopsy Market, By End Users, From 2021 to 2026 (USD Billion)
  19. North America Reference Laboratories Market, By Region, From 2021 to 2026 (USD Billion)
  20. North America Hospital/Physician Laboratories Market, By Region, From 2021 to 2026 (USD Billion)
  21. North America Academic and Research Centers Market, By Region, From 2021 to 2026 (USD Billion)
  22. North America Other End Users Market, By Region, From 2021 to 2026 (USD Billion)
  23. United States Liquid Biopsy Market, By Cancer Type, From 2021 to 2026 (USD Billion)
  24. United States Liquid Biopsy Market, By Sample Type, From 2021 to 2026 (USD Billion)
  25. United States Liquid Biopsy Market, By Diagnostic Approach, From 2021 to 2026 (USD Billion)
  26. United States Liquid Biopsy Market, By End Users, From 2021 to 2026 (USD Billion)
  27. Canada Liquid Biopsy Market, By Cancer Type, From 2021 to 2026 (USD Billion)
  28. Canada Liquid Biopsy Market, By Sample Type, From 2021 to 2026 (USD Billion)
  29. Canada Liquid Biopsy Market, By Diagnostic Approach, From 2021 to 2026 (USD Billion)
  30. Canada Liquid Biopsy Market, By End Users, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports


$ 1234 3335

Click for Request Sample